Hikal Ltd reported consolidated revenue of ₹403 crore for the quarter ended June 30, 2026, marking a 6.2% year-on-year growth despite geopolitical and macroeconomic headwinds. The company’s EBITDA expanded significantly by 47.4% to ₹37 crore, driven by an improvement in margins that widened by 260 basis points to 9.2%. However, Hikal recorded a net loss of ₹7 crore for the period, compared to a loss of ₹22 crore in the same quarter last year. The results reflect a transitional phase as the company moves from regulatory-led disruption toward growth, with management citing improving customer demand and execution-led performance.

The pharmaceutical business was the primary growth driver, delivering revenue of ₹233 crore, a 15.2% increase year-on-year. This segment accounted for 58% of total revenue, up from 53% in Q1FY26. The recovery was supported by strengthening demand in regulated markets and improved customer offtake across own products and CDMO operations. Conversely, the crop-protection business saw revenue decline to ₹170 crore from ₹178 crore in the previous year’s corresponding quarter, contributing 42% to the total mix. While own products delivered volume-led growth in domestic markets, CDMO demand remained subdued due to customer inventory adjustments and higher input costs stemming from geopolitical developments.

Financial Performance Overview

Jai Hiremath, Executive Chairman of Hikal Ltd., noted that Q1FY27 represented a slower start as the company transitions from regulatory remediation to growth. He highlighted that significant time and resources were invested in compliance with US FDA recommendations, which temporarily slowed sales in the pharmaceutical business due to planned plant shutdowns. The company is now in the penultimate stage of its remediation plan, with a reinspection expected during the current fiscal year. Hiremath expressed confidence in capitalizing on the CDMO pipeline and specialty APIs in oncology, CNS, gastroenterology, and complex chemistries.

What the Numbers Show

The divergence between revenue growth and net profitability highlights the operational leverage being regained by Hikal. While revenue grew modestly at 6.2%, EBITDA nearly doubled year-on-year, indicating that fixed costs are being absorbed more efficiently as volumes recover. However, the persistence of a net loss, albeit reduced from ₹22 crore to ₹7 crore, suggests that non-operating expenses or one-time charges may still be impacting the bottom line. The shift in revenue mix towards pharmaceuticals (58%) from crop protection (42%) also signals a strategic pivot towards higher-margin regulated markets, supported by an increased DMF filing trajectory of 5–6 filings annually compared to 2–3 historically.

Looking ahead, management expects business momentum to strengthen progressively through FY27. Key initiatives include the commissioning of a new cGMP pilot plant in Pune to enhance pharmaceutical development capabilities and the commercialization of the Personal Care business in July 2026. Additionally, Hikal received a Gold rating from EcoVadis, placing it in the top 5% of companies globally, which reinforces its positioning among global life sciences partners. The company remains focused on expanding CDMO opportunities and achieving operational excellence to drive stepwise recovery in revenues and profitability.

Hikal Limited will host an earnings group conference call on Thursday, August 06, 2026, at 5:00 PM IST to discuss its financial and operational performance for the quarter ended June 30, 2026. The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, providing investors with a direct channel to management for insights into Q1FY27 results. The company notified both the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the event. The intimation dated July 30, 2026, was signed by Company Secretary Rajasekhar Reddy Chintakindi, ensuring compliance with regulatory disclosure norms.

Conference Call Participants

Senior leadership from Hikal Limited will participate in the discussion to provide detailed commentary on the quarter's performance. The key participants are as follows:

Dial-In Details

Investors and analysts can join the call using the provided dial-in numbers. Strategic Growth Advisors Pvt. Ltd. is facilitating the registration process.

For RSVP inquiries, investors may contact Mr. Jigar Kavaiya at jigar.kavaiya@sgapl.net or Ms. Ami Parekh at ami.parekh@sgapl.net .

What This Means for Investors

The conference call serves as a critical platform for stakeholders to understand the drivers behind Hikal Limited's Q1FY27 financial results. With participation from the CFO and business heads, the session is expected to cover segment-wise performance, particularly in Pharmaceuticals and Animal Health, as well as broader business transformation initiatives. Investors should note that no specific financial figures were disclosed in this announcement; all material data will be presented during the live discussion.